文献速递白血病

同时靶向白血病起始细胞与白血病主体细胞可实现疾病根除

Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradication.
PubMed 文献 · Leukemia · 2022-03-04

研究利用不同白血病起始细胞(LIC)频率的急性早幼粒细胞白血病(APL)小鼠模型,比较丙戊酸(VPA)与伏立诺他(SAHA)联合全反式维甲酸(ATRA)对APL主体细胞和APL LIC的作用。结果显示VPA分化APL主体细胞,SAHA选择性靶向LIC,ATRA+VPA+SAHA在LIC频率较低的APL模型中有效诱导完全缓解(CR)。以依曲替酯替代ATRA会削弱该方案的疗效。

要点

  • VPA分化APL主体细胞,SAHA选择性靶向APL LIC。
  • ATRA+VPA+SAHA在LIC频率较低的APL模型中有效诱导CR。
  • 以依曲替酯替代ATRA会削弱ATRA+VPA+SAHA方案的疗效。

核心结论

  • 同时靶向LIC和白血病主体细胞可实现并维持完全缓解。
  • ATRA+VPA+SAHA联合方案在LIC频率较低的APL模型中有效诱导CR。
  • 以依曲替酯替代ATRA会削弱ATRA+VPA+SAHA方案的疗效。

研究设计与样本

  • 研究利用携带PML-RARα融合蛋白、具有不同LIC频率的急性早幼粒细胞白血病(APL)小鼠模型。

主要发现

  • VPA分化APL主体细胞,SAHA选择性靶向LIC。
  • ATRA+VPA+SAHA联合方案在LIC频率较低的APL模型中有效诱导CR。
  • 以依曲替酯替代ATRA会削弱ATRA+VPA+SAHA方案的疗效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

According to a hierarchical model, targeting leukemia-initiating cells (LICs) was speculated to achieve complete remission (CR) or cure. Nonetheless, increasing evidence emphasized the plasticity of differentiated blasts undergoing interconversion into LICs. We exploited murine models of acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia driven by the promyelocytic leukemia/retinoic acid receptor (PML-RARα) oncofusion protein, which recruits histone deacetylase (HDAC)-containing complexes. We studied APLs with different LIC frequencies and investigated the effect of two HDAC inhibitors: valproic acid (VPA), with relative selectivity towards class I HDAC enzymes and vorinostat/suberoylanilide hydroxamic acid (SAHA) (pan-HDAC inhibitor) in combination with all-trans retinoic acid (ATRA), on the bulk APL cells and APL LICs. Indeed, we found that while VPA differentiates the bulk APL cells, SAHA selectively targets LICs. ATRA + VPA + SAHA combination efficiently induced CR in an APL model with lower LIC frequency. Substituting ATRA with synthetic retinoids as etretinate which promotes APL differentiation without downregulating PML/RARα compromised the therapeutic benefit of ATRA + VPA + SAHA regimen. Altogether, our study emphasizes the therapeutic power of co-targeting the plasticity and heterogeneity of cancer -herein demonstrated by tackling LICs and bulk leukemic blasts - to achieve and maintain CR.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Moretti S, Abdel-Aziz AK, Ceccacci E, et al. Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradication. Leukemia. 2022. PMID: 35246604. doi:10.1038/s41375-022-01530-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。